Right ventricular failure (RVF) after left ventricular assist device (LVAD) implantation is associated with increased morbidity and mortality, but the identification of LVAD candidates at risk for RVF remains challenging. We undertook a systematic review and meta-analysis of observational studies of risk factors associated with RVF after LVAD implant. Thirty-six studies published between 1 January 1995 and 30 April 2015, comprising 995 RVF patients out of a pooled final population of 4428 patients, were identified. Meta-analysed prevalence of post-LVAD RVF was 35%. A need for mechanical ventilation [odds ratio (OR) 2.99], or continuous renal replacement therapy (CRRT; OR 4.61, area under the curve 0.78, specificity 0.91) were the clinical variables with the highest effect size (ES) in predicting RVF. International normalized ratio [INR; standardized mean difference (SMD) 0.49] and N-terminal pro-brain natriuretic peptide (NT-proBNP) (SMD 0.52) were the biochemical markers that best discriminated between RVF and No-RVF populations, though NT-proBNP was highly heterogeneous. Right ventricular stroke work index (RVSWI) and central venous pressure (CVP) (SMD −0.58 and 0.47, respectively) were the haemodynamic measures with the highest ES in identifying patients at risk of post-LVAD RVF; CVP was particularly useful in risk stratifying patients undergoing continuous-flow LVAD implant (SMD 0.59, P < 0.001, I 2 = 20.9%). Finally, pre-implant moderate to severe right ventricular (RV) dysfunction, as assessed qualitatively (OR 2.82), or a greater RV/LV diameter ratio (SMD 0.51) were the standard echocardiographic measurements with the highest ES in comparing RVF with No-RVF patients. Longitudinal systolic strain of the RV free wall had the highest ES (SMD 0.73) but also the greatest heterogeneity (I 2 = 74%) and was thus only marginally significant (P = 0.05). Patients on ventilatory support or CRRT are at high risk for post-LVAD RVF, similarly to patients with slightly increased INR, high NT-proBNP or leukocytosis. High CVP, low RVSWI, an enlarged right ventricle with concomitant low RV strain also identify patients at higher risk.
Introduction
Heart transplantation is considered the gold-standard therapy for end-stage heart failure (HF), but is limited by insufficient donor supply. At present, implantable left ventricular assist devices (LVADs) represent the only available and effective alternative to heart transplantation, and provide a broad spectrum of strategies, including bridge to heart transplantation (BTT) or recovery, or destination therapy (DT). 1 However, given that LVADs support only the left ventricle, immediately after device implantation the right ventricle is exposed to the risk of developing severe dysfunction, i.e. right ventricular failure (RVF): 2, 3 the LVAD decompresses the left ventricle causing a leftward shift of the interventricular septum, which results in a more spherical shape of the right ventricle, thus reducing the mechanical contractile properties of the right-sided chambers. In addition, right ventricular (RV) haemodynamics change after LVAD implantation because RV output must match that of the flow generated by the device. Right ventricular failure can be a fatal complication usually presenting within 2 weeks after device implantation. 4 It requires specialized intensive care management and portends a worse prognosis in the short as well as the long term. 5 Unfortunately, several aspects of RVF following LVAD implant are still uncertain, and even the reported prevalence of RVF in this population has been variable (ranging between 13% and 51%). 6 Careful postoperative management is becoming increasingly important, in particular identifying factors associated with adverse postoperative outcomes by means of renal or liver function testing as well as echocardiographic or right heart catheterization measurements. An analysis of the profile of patients with RVF compared with patients without RVF is needed to understand and determine predictors of RVF. Therefore, we systematically reviewed all studies comparing patients developing RVF shortly after LVAD implant (RVF group) with patients who did not develop acute RVF (No-RVF group). Subsequently, we employed a meta-analytic strategy with a twofold aim: (i) to determine pooled, final proportion of RVF in this specific study population, and (ii) to identify clinical, laboratory, haemodynamic or echocardiographic parameters that best discriminated between patients with and without RVF, according to effect size (ES) computation rather than P-values or risk score systems.
Methods

Data sources and search strategy
We systematically searched OVID databases of MEDLINE and EMBASE, as well as Scopus, Web of Science and Google Scholar from 1 January 1995 to 30 April 2015. Search terms included 'right ventricular mechanical support', 'right ventricular failure', 'right heart failure', 'ventricular assist device', 'cardiac assist device', 'predictors', 'prognosis', 'outcomes', 'adverse events', 'complications', 'survival', 'risk stratification', 'patient selection', 'haemodynamics', 'echocardiography', and 'biomarkers' combined with 'advanced heart failure'. The search was limited to human studies; no language or age restrictions were imposed. We also searched the Cochrane Library for any recent systematic review on the subject. Hand search of the following meetings in the years 1995-2014 was also performed as well: American College of Cardiology, American Heart Association, European Society of Cardiology, Heart Failure Society of America, Heart Failure Association and European Society of Organ Transplantation. We also asked experts in the field to provide additional evidence.
Searches from different engines were then combined, and duplicated results were deleted. Two investigators (D.B. and A.I.) went through the results of original search independently. The two investigators had to reach a consensus on the eligibility of all articles.
We executed and reported our findings according to the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) 7 . . . and Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 8 statements.
Selection criteria (inclusion/exclusion)
We made a first screening of title and abstract identifying those records that considered patients with overt HF, referred to either pulsatile flow (PF-) or continuous flow (CF-) LVADs, and in which a proportion of the whole recruited population developed RVF acutely (i.e. within 2 weeks of LVAD implantation). At level 2 screening, full manuscripts were obtained for all publications accepted at level 1 screening. At this stage, we verified that relevant data were available and that multiple publications describing the same study population were clustered and entered only once in the quantitative syntheses. We included studies that met the following criteria: data were stratified for both RVF and No-RVF patients; data were expressed as n (%) or mean ± standard deviation and included clear denominators; more than 10 patients were referred for LVAD implant. At this stage, the bibliographies of the articles and of reviews and meta-analyses were scanned to identify additional references. Finally, level 3 screening focused on quality and relevance assessment (see next section) of the studies selected at level 2 screening.
Several studies were excluded if they: (i) focused on the consequences of RVF (i.e. morbidity or mortality following RVF) without reporting the baseline (i.e. pre-LVAD) characteristics of the population; (ii) assessed the efficacy of a specific strategy [either a particular medication or specific RV/biventricular assist device (RVAD/BiVAD)] for managing RVF after LVAD implant; (iii) were reported in abstract forms, book chapters, case reports or narrative reviews; or (iv) included neonatal/paediatric populations (i.e. 17 years old or younger). If a study included patients referred for BiVAD implant because of the anticipated prohibitive risk of RVF, the group that underwent planned BiVAD implant was excluded a priori.
Data abstraction
As our primary outcome was to assess the overall prevalence of RVF across studies, we adopted a fairly inclusive definition of RVF that included: need for intravenous inotropes for >2 weeks; or persistent RV stroke work index (RVSWI) <4.0 g/m 2 ; or nitric oxide inhalation for >48 h at any rotation speed or saline infusion; presence of acute RVF when emergent/urgent need for mechanical RV support (i.e. RVAD implant in addition to the previously implanted LVAD) was considered mandatory by the HF team in charge. 5 Consensus was also required on each predetermined variable reported in the data collection form (see Results section for the full list of collected variables); any disagreement led to a new revision of the critical issue by two reviewers, and any persisting disagreement was solved in conference; in selected cases, conflicting data recordings were solved by an independent evaluator (J.M.). Two reviewers abstracted the data independently (D.B. and A.I.). A centralized, online web-based relational database system was developed (Filemaker version 11.1; FileMaker, Inc., Santa Clara, CA, USA) with the specific purpose of storing and maintaining a single, highly organized data repository for studies focused on RVF after LVAD placement. The following information was collected from each study: year of publication, study acronym and identifier, first author's last name, geographic location of study, start and end of study dates, economic support, clinical setting (inpatients vs. outpatients) and collaboration setting (single-centre vs. multicentre study). Moreover, from each study, we retrieved study population characteristics (age range, gender distribution, geographic area, ethnicity), inclusion/exclusion criteria, New York Heart Association (NYHA)/Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) class, aim of treatment in referring to LVAD implant, such as BTT or DT, type of LVAD implanted (PFor CF-LVAD), study design characteristics (case-control, or retrospective vs. prospective cohort), follow-up time, sample size, and RVF assessment. Mean and variability measure for each potential predictor of RVF was reported, as well as estimates of magnitude of association and variability [i.e. standard errors or 95% confidence intervals (CI)] were extracted over the entire study samples and/or by subgroups. In the event that variables were presented in different scales (notably mmol/L instead of mg/dL, or g × mL/m 2 instead of mmHg × mL/m 2 ), conversions were applied so as to have a unified and consistent scale.
Methodological quality
In order to assess quality of the observational studies included, an 18-criterion checklist was used that has been developed through a modified Delphi technique. 9 The sum of positive items based on reviewers' consensus was counted for each study. The maximum score for a study was 18 as each criterion was weighted equally. A study with 14 or more 'yes' responses (70%) was considered to be of high quality and therefore included in the meta-analysis.
Statistical analyses
Proportions and standard errors (SE) of RVF were calculated using the following formulae: p = r/n and SE = √ p(1 -p)/n, where r is the number of RVF occurrences and n is the number of No-RVF occurrences. The variances were calculated by the formula: v(lp) = 1/(np) + 1/[n(1 − p)], where v is variance and n is the sample size. A zero value reported for the numbers of RVF or No-RVF was imputed as 0.5. Standardized mean difference (SMD) was considered as suggestive of a small (>0.2), intermediate (>0.5), or large (≥0.8) ES, as suggested by Cohen.
10 The P-value for the overall summary ES was calculated using a Z-score, where the numerator was the natural logarithm of the pooled ES and the denominator was the standard error of the natural logarithm of the pooled ES. This is a standard method for calculating the P-value using Peto's Assumption-Free Method. 11 In order to assess sensitivity, specificity, and prognostic accuracy of the categorical covariates with the highest ES [i.e. the greatest odds ratio (OR)], a hierarchical bivariate generalized linear mixed model was applied, as proposed by Harbord et al., 12 using the Stata program METANDI (Stata-Corp LP, College Station, TX, USA). Based on this model, the elliptical joint confidence region for sensitivity and specificity and a hierarchical summary receiver operating characteristic (HSROC) curve were constructed. In addition, area under the curve (AUC)-ROC values with 95% CI and cut-off values for each categorical covariate weighted for sample size were pooled. 13 
Heterogeneity assessment and moderator analysis
Considering the observational nature of available studies, a high grade of heterogeneity was expected, so random-effects models using DerSimonian and Laird method for variance estimator were implemented to study the net impact of each 'predictor' on the risk of RVF, independently of the Higgin's I 2 value. 14 across study estimates is presented as Q-statistic and the I 2 value. In order to explain between-studies heterogeneity, a moderator analysis was performed using subgroup analysis, as well as random effects meta-regression techniques. In particular, pooled estimates of predetermined covariates were considered for the following subgroups: by study design (i.e. retrospective vs. prospective), by proportion of enrolled females in the total population (≤25% vs. >25%), by proportion of CF-LVADs implanted (≤75% vs. >75%), by proportion of ischaemic cardiomyopathy as main cause of HF (≤50% vs. >50%), and by proportion of BTT aim of treatment (>75% vs. ≤75%). Furthermore, to complete moderator analysis, univariate random effects meta-regression was used to explore potential sources of heterogeneity across estimates with the following covariates obtained in the pre-LVAD implant period: year of publication, age, gender distribution, heart rate, albumin, total bilirubin, transaminases, blood urea nitrogen and creatinine levels, platelet and white blood cell (WBC) counts; left ventricular (LV) and RV end-diastolic diameters (detected at the basal level), LV ejection fraction and RV fractional area change, tricuspid annular plane systolic excursion (TAPSE) on echocardiography; cardiac output and cardiac index, systolic, diastolic and mean arterial systemic pressure, as well as systolic, diastolic, mean pulmonary artery pressure, systemic and pulmonary vascular resistance, pulmonary capillary wedge pressure (PCWP), and transpulmonary gradient. These were all obtained invasively by right heart catheterization. Single study omitted influence analyses were done to assess the sensitivities of pooled estimates.
Publication bias was evaluated visually by funnel plots with pseudo 95% CIs, while Egger's regression asymmetry test and Begg's coefficient were used to test the significance of funnel plot asymmetries. Assessment of publication bias was performed when ≥10 studies were available for meta-analysis.
Identification of the most significant clinical predictors of RVF was based not merely on the computed P-value, but primarily on quantification of ES (obtained as either SMD or OR for continuous or categorical variables, respectively), and concomitant heterogeneity (the lower the better). STATA software version 13.1 (StataCorp LP, College Station, TX, USA) was used for all data analyses.
Results
Study selection
We identified 612 citations from our initial electronic database search, with 84 duplicated studies that were excluded. Of the remaining 528 unique studies, 41 articles were identified for full text review. A further six articles were identified through manual search, bibliographic search, and reviewer suggestions. A flow diagram detailing the process of study identification and selection is shown in Figure 1 . The Cohen -statistic for agreement on study inclusion was 0.92.
Study characteristics
Thirty-six articles reported the outcome of interest and contributed to the meta-analyses. All were published in English, evaluating RVF prevalence from four continents ( 
Meta-analyses
Pooled prevalence of right ventricular failure Figure 2 depicts forest plots of the proportion of RVF, stratified by study design (case-control vs. prospective cohorts, Figure 2A ) and proportion of CF-LVADs implanted (>75% vs. ≤75% of enrolled patients, Figure 2B ). According to subgroup analysis, RVF prevalence was 35% and homogeneous (I 2 = 0.00) in prospective cohort studies, while it was 23% but substantially heterogeneous (I 2 = 90.4%, P < 0.001) when data were pooled from case-control studies. Because of the importance of the observed heterogeneity across retrospective studies, prospective and retrospective studies were not cumulated. Right ventricular failure was 28% when the percentage of CF-LVAD implanted was >75% of the whole population and 23% when the percentage was ≤75% (i.e. in studies where PF-LVADs were implanted in a significant number of recruited patients). However, heterogeneity was substantial in both subgroups. According to meta-regression analysis, year of publication was not related to RVF prevalence, while the higher the WBC count, the higher the proportion of RVF in the population ( = 0.05, P = 0.04; Figure 2C ).
Covariate analysis: overall and stratified meta-analyses
Predetermined covariates ( Table 2 ) were pooled and meta-analysed, and ES as well as measures of heterogeneity were obtained. All meta-analyses were subsequently stratified by criteria described in the Methods section, and Table 3 reports meta-analyses by proportion of CF-LVADs implanted in the population of each study. The most significant predictors of RVF are reported in Table 4 : following a meta-analytical strategy, identification of such measurements was based on ES and heterogeneity, not merely on computed P-value.
Demographic, anthropometric, and clinical characteristics
Age was not different in RVF compared with No-RVF patients, while patients developing RVF had a significantly lower body surface area (BSA) (SMD −0.20; P < 0.001), specifically in studies where patients receiving CF-LVADs were <75% of the population. Female gender was associated with higher risk of developing RVF after LVAD implant (OR 1.60; P < 0.001), but pooled OR was heterogeneous and driven by studies with proportion of CF-LVADs implanted < 75%. Need for an intra-aortic balloon pump (IABP) pre-LVAD implant was associated with higher risk of developing RVF post-procedure (OR 1.59, P = 0.03; Table 2 ). According to HSROC, the AUC depicting accuracy of need for IABP in discriminating between RVF and No-RVF patients was 0.57 (specificity 0.81, sensitivity 0.27). The need for mechanical ventilation also increased the risk of RVF (OR 2.99, P < 0.001; see the Supplementary material online, Figure S1 ) and the effect was maintained even in studies enrolling >75% of patients referred for CF-LVAD placement, or those recruiting >25% of females (OR 3.26, P < 0.001). The HSROC-AUC was 0.67, with a sensitivity of 0.38 and a specificity of 0.83. Age and total bilirubin were significant modifiers of the relation between ventilatory support and RVF ( for age = −0.033, P = 0.01; for total bilirubin = 2.27, P = 0.03).
Patients needing dialysis or other form of continuous renal replacement therapy (CRRT) at baseline were at higher risk of RVF than patients not requiring CRRT (OR 4.61, P < 0.001; Figure 3A) ; ES was homogeneous but it was computed pooling the only four studies reporting this covariate, so that subgroup analysis was not performed. The HSROC-AUC for dialysis/CRRT was 0.78 with a specificity of 0.91 ( Figure 3B ). Further analyses on pre-specified subgroups did not show any significant difference in SMD or heterogeneity for the above-mentioned covariates (data not shown), and according to meta-regression, being of female gender significantly influenced the relationship between CRRT establishment and RVF ( Figure 3C ). 
Circulating biomarkers
Pooled Table S1 and Figure S2 ). Liver function panel showed higher pooled international normalized ratio (INR) in RVF patients compared with No-RVF patients (SMD 0.48, P < 0.001, Figure 4) ; results were homogeneous, and Figure S3 ). However, INR-related ES was higher in patients with primary, non-ischaemic cardiomyopathy than in patients with ischaemic aetiology (SMD 0.61 and 0.29, respectively; see the Supplementary material online, Table S1 ). According to meta-regression, cardiac index and pulmonary vascular resistance were significant determinants of heterogeneity in pooled SMD ( for cardiac index = −0.98, P = 0.008; for pulmonary vascular resistance = 0.006, P = 0.01). Albumin level was lower, while total bilirubin as well as both aspartate transaminase (AST) and alanine transaminase (ALT) levels were higher in patients developing RVF compared with patients without this complication. Aspartate transaminase ES in particular was intermediate (SMD 0.52, P < 0.001) but highly heterogeneous. According to renal function panel, both pooled creatinine and blood urea nitrogen levels were higher in the RVF group than in the No-RVF group. Studies that measured N-terminal pro-brain natriuretic peptide (NT-proBNP) level in the two groups of interest provided highly heterogeneous results (I 2 = 70.4%, P < 0.001; Figure 5) ; overall, NT-proBNP was higher in the pooled population of RVF patients compared with No-RVF patients, with intermediate, marginally significant ES (SMD 0.52, P = 0.05). According to meta-regression, the proportion of females enrolled was the only significant explanatory variable of the association between NT-proBNP and RVF: the higher the proportion of females enrolled in the study, the lower the difference in NT-proBNP level between RVF and No-RVF groups ( = −10.55, P = 0.03), as confirmed by stratified analysis by gender (see the Supplementary material online, Table S2) . NT-proBNP level was also more important as a predictor in patients with ischaemic dilated cardiomyopathy compared with those with non-ischaemic aetiology (SMD 0.70 vs. 0.40; see the Supplementary material online, Table S1 ).
Haemodynamic parameters (right heart catheterization)
The RVSWI was the measure with the highest ES, being systematically lower in RVF than in No-RVF patients (SMD −0.58, P < 0.001; Figure 6 ), considering studies with either retrospective or prospective design (SMD −0.59 and P < 0.01 for both). However, pooled ES was influenced by the type of LVAD (CF-or PF-) implanted: studies with ≥75% of enrolled patients receiving CF-LVADs had a homogeneously low ES (−0.37, P < 0.001, I 2 = 27%) compared with a greater but heterogeneous ES in studies where the proportion of patients receiving CF-LVADs was <75% (SMD −0.69, P < 0.001, I 2 = 54.2%). According to meta-regression, systolic pulmonary artery pressure was a significant determinant of heterogeneity in the ES of RVSWI between RVF and No-RVF patients ( = 0.06, P = 0.04). Finally, RVSWI was particularly reduced in the two groups considering studies that enrolled >25% of females (SMD −0.69, P < 0.001; see the Supplementary material online, Table S2 ).
Pooled central venous pressure (CVP) was higher in the RVF group than in the No-RVF group (SMD 0.47, P < 0.001; Figure 7 ). Subgroup analysis showed that ES was higher in studies where >75% of enrolled patients received CF-LVADs (SMD −0.59, Together with RVSWI, it is the haemodynamic predictor with the greatest effect size, specifically in patients undergoing CF-LVAD implantation Echocardiography Moderate-to-severe RVD This relatively simple, pure qualitative assessment of RV performance is extremely predictive of RVF, and should be part of routine echocardiographic evaluation in patients considered for LVAD. High RV/LV ratio To date, the RV/LV ratio obtained in a four-chamber apical view is the single most significant quantitative echo measurement able to define risk of RVF in LVAD recipients. Low longitudinal sS of the RV free wall Although sS of the right ventricle is very promising, and probably useful, there is too much variability in measures and there are too few published studies to reach a definitive conclusion. While PCWP and systolic and diastolic arterial pressure did not differ between RVF and No-RVF patients, pooled mean systemic arterial pressure was lower in RVF patients (SMD −0.29, P < 0.001). Subgroup analysis showed that ES was higher in studies with a greater prevalence (≥75%) of CF-LVADs implanted than in studies where <75% of patients received a CF-LVAD (Table 3) as well as in studies enrolling >25% of females (SMD −0.48 vs. -0.28; see the Supplementary material online, Table S2 ). According to meta-regression, both RVSWI ( = 0.0021, P = 0.03) and mean pulmonary artery pressure ( = −0.08, P = 0.03) were significant determinants of heterogeneity in the relationship between mean arterial pressure (MAP) and RVF.
. Both cardiac output and cardiac index were lower in the RVF group compared with the No-RVF group (SMD −0.30 and −0.22, respectively; P < 0.01 for both). Finally, transpulmonary gradient was higher and marginally significant in the RVF group compared with the No-RVF group (SMD 0.27, P = 0.06). Subgroup analysis did not help in other ways than previously reported to explain heterogeneity for haemodynamic covariates.
Echocardiography
Having either moderate to severe RV dysfunction (assessed by qualitative inspection of two-dimensional images) was associated with higher risk of RVF (OR 2.82, P < 0.001); ES was higher in studies where <75% of patients underwent CF-LVAD implant ( Table 3) . According to HSROC analysis, AUC was 0.68. Among quantitative echocardiographic measures, pooled LV end-diastolic diameter was lower in patients who developed RVF (SMD −0.40, Figure 3 Forest plot, hierarchical summary receiver operating characteristic (HSROC) plot, and meta-regression bubble plots of the pooled estimate of the impact of dialysis/continuous renal replacement therapy (CRRT) on right ventricular failure (RVF). (A) Forest plot of the impact of dialysis/CRRT on RVF (analysis not stratified). (B) HSROC plot of dialysis/CRRT to predict RVF. Combined sensitivity [95% confidence interval (CI)] and specificity (95% CI) weighted for sample size of each data set is reflected by the size of the circles, showing average sensitivity and specificity estimate of the study results (solid squares) and a 95% confidence region around it. (C) Bubble plot of female gender proportion on the effect size of dialysis/CRRT and RVF. AUC, area under the curve; CI, confidence interval; OR, odds ratio. P < 0.001), and the overall ES was influenced by studies with a significant proportion of PF-LVADs also implanted by VAD strategy adopted (BTT vs. DT) being higher in patients with a DT strategy compared with those implanted as BTT (SMD −0.41 and −0.24, respectively; see the Supplementary material online, Table S3 and . . . . . . . . . . . . . Figure S4 ). The RV end-diastolic diameter was higher while RV fractional area change was lower in RVF vs. No-RVF patients (SMD 0.31 and −0.29, respectively, P < 0.001 for both). Pooled TAPSE and tricuspid regurgitation of more than moderate grade did not differ between groups, while RV/LV diameter ratio was significantly Figure 8A ). According to meta-regression, the proportion of enrolled females was the only significant moderator accounting for heterogeneity in RV/LV ratio ES: the higher the number of females enrolled, the lower the SMD obtained. Consistently, stratified analysis by gender showed that RV/LV ratio had minimal importance in studies enrolling a high proportion of females, while ES was very high in studies where females were not represented (SMD 0.16 vs. 0.84; see the Supplementary material online, Table S2 ). The RV free wall longitudinal systolic strain (sS) was increased (i.e. less negative) in patients who developed RVF compared with those without this complication, and ES was large but marginally significant (SMD 0.73, P = 0.05; Figure 8B ). Notably, RV longitudinal sS was highly heterogeneous (I 2 = 74%, P = 0.01) despite the fact that only three studies reported this measurement. Meta-regression was unable to identify moderators to explain heterogeneity in longitudinal sS ES. Finally, heterogeneity in echocardiographic measurements was not explained by study design, prevalence of enrolled females, aim of treatment (BTT vs. DT), or prevalence of ischaemic cardiomyopathy in the population.
. 
Publication bias and quality assessment
Formal statistical tests to determine probability of publication bias are reported in the Supplementary material online, Table 4S . According to Egger's asymmetry test, Begg's test, or Kendal's score, there was no obvious publication bias among covariates undergone meta-analysis. The Supplementary material online, Table 5S , lists the results of the qualitative analysis performed according to the checklist implemented: although all studies included had >70% of positive answers, most of them were conducted in a single centre, patients often were not recruited consecutively (or sequence of enrolment was not mentioned), and follow-up time was reported only in a small proportion of them.
Discussion
To our knowledge, this is the first systematic review and meta-analysis aimed at identifying independent predictors of acute RVF in patients referred for LVAD implantation, according to currently available evidence: CRRT and ventilatory support appeared correlated with risk of RVF occurrence after LVAD implantation. These predictors are associated with good specificity, and thus high positive predictive power, but low sensitivity and negative predictive value, indicating that although RVF can often occur after LVAD implantation even in patients without preoperative CRRT or ventilatory support, their preoperative necessity is highly predictive of post-LVAD RVF. This is explainable because patients with respiratory insufficiency and/or renal failure are less likely to show improvement of RV loading conditions during LVAD support. High NT-proBNP levels, INR, or WBC count are correlated with RVF, as well high CVP, low RVSWI and MAP. Finally, longitudinal sS of RV free wall is the echocardiographic measure that was associated with the occurrence of post-LVAD RVF. Notably, the RV/LV diameter ratio and the simple, qualitative identification of more than moderate RV dysfunction by echocardiography are also accurate predictive measures of RVF. In the present work, we have tested the role of a variety of clinical, humoral, morphological, and haemodynamic parameters in the pathogenesis of RVF following LVAD implantation according to several studies: no single measurement has been shown sensitive or specific enough to predict RVF with a clinically acceptable accuracy. Beyond single predictors, several risk scoring systems have been suggested by many authors. Although each score seems promising when applied to the same study population used to define the model, predictive accuracy drops dramatically when the score is employed in a different population. Recently, Pettinari et al. 33 published a retrospective study on 59 patients referred for LVAD where three RVF risk scores were calculated: the study revealed that these scores failed to predict the actual need for RV support after LVAD implantation. This might also be related to differences in RVF definition and selection criteria for ventricular assist device implantation. 
Overall analysis on right ventricular failure prevalence in patients referred for left ventricular assist device implantation
In the present analysis, all predictors (i.e. covariates) of post-LVAD RVF reported in the literature were assessed in our large systematic review (a summary of identified predictors of RVF with a brief comment is reported in Table 3 ). Although when looking just at P-values several variables were significantly related to RVF, according to more appropriate ES computation, these predictors had at best a modest correlation with the occurrence of RVF. The only predictors strongly associated with RVF were INR and CVP. We were also able to explain some of the variance observed across studies by type of LVAD implanted (CF-vs. PF-), female gender, or primary cause of dilated cardiomyopathy/HF with reduced ejection fraction (ischaemic vs. non-ischaemic). The prevalence of RVF complications did not appear to decrease after CF-LVADs have gained widespread use. In this regard, the results of our meta-analysis conflict with other reports. 29, 51 One reason for this difference might be related to the significant number of is associated with an increased and significant risk of RVF. This observation could be related, at least partly, to lower BSA and LV end-diastolic diameter in females compared with males. Although gender seems to be a more relevant factor in patients referred for PF-LVAD compared with CF-LVAD, studies enrolling a significant (i.e. >25%) proportion of females have highlighted the importance of haemodynamic parameters such as RVSWI or MAP in this population, while other echocardiographic measures, primarily the RV/LV ratio, have been found to be less important. The need for IABP, mechanical ventilation, or CRRT in the immediate pre-implant period confers a substantially higher risk of post-LVAD RVF. This observation is consistent across studies, independent of type of LVAD implanted, gender, or aim of treatment, with an OR particularly high for CRRT. Interestingly, these covariates have good to high specificity (>0.90 for CRRT) and thus have great positive predictive power, but at the cost of poor sensitivity (and negative predictive power). Low sensitivity of such covariates affects their overall predictive accuracy, probably because these therapeutic strategies are usually employed in advanced stages of HF. biomarker in this context probably results from the relationship between significant RV dysfunction and consequent venous liver congestion. Consistent with previous reports, 52 the main moderators of the relationship between INR and RVF were a reduced cardiac index and high pulmonary vascular resistance, while CVP was not significant. Interestingly, differences in INR between groups were also not clinically significant: indeed, INR was on average ≤1.5 for both groups. The WBC count was also increased in RVF patients compared with No-RVF patients, with a moderate ES. Interestingly, this association was influenced by primary aetiology of HF, with ES being higher in patients with ischaemic vs. non-ischaemic cardiomyopathy, perhaps because of a reasonable but undemonstrated association between coronary artery disease, peripheral/systemic arterial disease, chronic ischaemia, and recurrent inflammatory response. This observation, together with the role of WBC count as main moderator or RVF prevalence, highlights not only the well-known risk from infections in these patients, but also suggests a significant role of systemic infection/inflammation in inducing or worsening impairment of the right ventricle, specifically in patients with subclinical myocardial ischaemia.
Usefulness of cellular or biochemical markers
Invasive haemodynamics for the prediction of right ventricular failure
Looking at measurements collected in the cath-lab, RVSWI has been previously suggested to be one of the most significant values to consider in stratifying risk of RVF in patients referred for LVAD implantation and is currently included in the most recent guidelines. 5 We were able to confirm that RVSWI is lower in RVF patients compared with No-RVF patients, with an overall significant and intermediate ES. However, subgroup analysis suggested a different perspective: RVSWI is a powerful discriminator between RVF and No-RVF patients primarily when PF-LVADs are implanted, while its predictive accuracy is smaller in patients referred for the most used CF-LVADs. Interestingly, RVSWI may be more useful in females than in males.
Central venous pressure was consistently higher in patients developing RVF than in patients not developing this complication, but ES was even greater (i.e. more than moderate) in patients referred for CF-LVAD placement. A similar trend was observed for MAP: global ES was small overall, but improved substantially when looking at recent studies implanting a greater proportion of CF-LVADs.
Finally, it is worth mentioning that invasively measured cardiac index, and systemic or pulmonary pressures and resistances (other than MAP) were not very helpful in identifying patients with RVF, as these had small and inconsistently significant ESs.
Standard and strain echocardiography to predict right ventricular failure after left ventricular assist device implantation
Echocardiography has traditionally played a critical and unquestioned role in risk stratification of patients with cardiovascular diseases in general and advanced HF in particular. In regard to prediction of RVF, it is noteworthy that TAPSE, although showing a trend towards being lower in RVF vs. No-RVF patients, had a small, non-significant ES, and was highly heterogeneous. Because longitudinal shortening accounts for a larger proportion of overall RV function, TAPSE has been shown to have a good correlation with RV ejection fraction measured by radionuclide angiography and a prognostic value in HF patients. 53, 54 Despite these advantages, several other studies have revealed important disadvantages, such as the well known load dependency and overlooking septal contribution to RV ejection, which is important to maintain RV function after LVAD implantation. All these limitations may account for the variability of TAPSE observed across the studies. Similarly, both RV end-diastolic diameter and RV fractional area change had a small ES in discriminating the two groups. In contrast, a purely qualitative assessment of RV performance, showing more than moderate dysfunction of the right chamber, is highly predictive of RVF. 
Limitations
The main limitation of the present meta-analysis is the design of included studies, because both retrospective and prospective observational studies are exposed to several biases (primarily selection bias, information bias, and confounding). Although we performed a thorough assessment of their methodological quality, the risk of bias, being inherent to the study design, cannot be ruled out completely. Our study is primarily focused on risk stratification of post-LVAD acute RVF. Although the pathophysiology of chronic RVF in patients with LVAD is equally important, the aetiology and predictors of such a complication are likely substantially different, so that our observations cannot be applied to that setting.
Although PF-LVADs are now less commonly used than CF-LVADs, the prevalence of RVF was comparable between these two types of LVADs. However, PF-LVADs are still employed in specific populations (such as paediatric patients) and we decided to include them in our analysis but, in addition to the pooled analysis, we also provided a stratified analysis to differentiate results according to LVAD type.
Beyond standard measurements, the studies included have often tested the usefulness of novel biomarkers (e.g. markers of inflammation or extracellular matrix), 47 innovative echocardiographic parameters, 19, 40 or combined measures (such as CVP/PCWP ratio), which have shown promise in stratifying the risk for RVF. Unfortunately, because these reports are novel and/or isolated, these variables were not included in the present meta-analysis.
Conclusions
Few clinical characteristics, in particular need for CRRT or mechanical ventilation, show adequate specificity for the occurrence of RVF but they have very low sensitivity. Among humoral markers, INR (even slightly increased over 1.1), NT-proBNP, and WBC count may be helpful for the identification of patients at risk. Invasive haemodynamic assessment should be focused on CVP, RVSWI, and MAP. Finally, qualitative assessment of RV performance, RV/LV diameter ratio and RV free wall longitudinal two-dimensional strain could be adopted in routine echocardiographic evaluation of these patients. We would like to emphasize that ESs obtained in the present work were intermediate at best, showing substantial overlapping values between RVF and No-RVF groups. Therefore, our meta-analysis highlights that available measurements obtained in daily clinical practice are insufficient to identify with acceptable accuracy those patients referred for LVAD implantation who will develop RVF. The role of these factors in risk stratification algorithms is highly dependent on the type of patients under study. Simply summing in a single risk algorithm might not solve the problem of difficult prediction.
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